User profiles for Sebastian Palmqvist
 | Sebastian Palmqvist, MD, PhDAssociate professor at Lund University, Consultant Neurologist at Skåne University Hospital … Verified email at med.lu.se Cited by 15038 |
Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders
Importance There are limitations in current diagnostic testing approaches for Alzheimer
disease (AD). Objective To examine plasma tau phosphorylated at threonine 217 (P-tau217) as …
disease (AD). Objective To examine plasma tau phosphorylated at threonine 217 (P-tau217) as …
Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia
Plasma phosphorylated tau181 (P-tau181) might be increased in Alzheimer’s disease (AD),
but its usefulness for differential diagnosis and prognosis is unclear. We studied plasma P-…
but its usefulness for differential diagnosis and prognosis is unclear. We studied plasma P-…
[HTML][HTML] Plasma β-amyloid in Alzheimer's disease and vascular disease
S Janelidze, E Stomrud, S Palmqvist, H Zetterberg… - Scientific reports, 2016 - nature.com
Implementation of amyloid biomarkers in clinical practice would be accelerated if such
biomarkers could be measured in blood. We analyzed plasma levels of Aβ42 and Aβ40 in a …
biomarkers could be measured in blood. We analyzed plasma levels of Aβ42 and Aβ40 in a …
Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective …
Background CSF and PET biomarkers of amyloid β and tau accurately detect Alzheimer's
disease pathology, but the invasiveness, high cost, and poor availability of these detection …
disease pathology, but the invasiveness, high cost, and poor availability of these detection …
[HTML][HTML] Differential roles of Aβ42/40, p-tau231 and p-tau217 for Alzheimer's trial selection and disease monitoring
Blood biomarkers indicative of Alzheimer’s disease (AD) pathology are altered in both
preclinical and symptomatic stages of the disease. Distinctive biomarkers may be optimal for the …
preclinical and symptomatic stages of the disease. Distinctive biomarkers may be optimal for the …
[HTML][HTML] Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline
…, C Groot, R Smith, O Strandberg, S Palmqvist… - Nature medicine, 2022 - nature.com
A major unanswered question in the dementia field is whether cognitively unimpaired
individuals who harbor both Alzheimer’s disease neuropathological hallmarks (that is, amyloid-β …
individuals who harbor both Alzheimer’s disease neuropathological hallmarks (that is, amyloid-β …
[HTML][HTML] Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity
It is not known exactly where amyloid-β (Aβ) fibrils begin to accumulate in individuals with
Alzheimer’s disease (AD). Recently, we showed that abnormal levels of Aβ42 in cerebrospinal …
Alzheimer’s disease (AD). Recently, we showed that abnormal levels of Aβ42 in cerebrospinal …
Prediction of future Alzheimer's disease dementia using plasma phospho-tau combined with other accessible measures
A combination of plasma phospho-tau (P-tau) and other accessible biomarkers might provide
accurate prediction about the risk of developing Alzheimer’s disease (AD) dementia. We …
accurate prediction about the risk of developing Alzheimer’s disease (AD) dementia. We …
Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer's disease
Although recent clinical trials targeting amyloid-β in Alzheimer’s disease have shown promising
results, there is increasing evidence suggesting that understanding alternative disease …
results, there is increasing evidence suggesting that understanding alternative disease …
Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease
Objective: To compare the diagnostic accuracy of CSF biomarkers and amyloid PET for
diagnosing early-stage Alzheimer disease (AD). Methods: From the prospective, longitudinal …
diagnosing early-stage Alzheimer disease (AD). Methods: From the prospective, longitudinal …